Background. The Surgery Versus Active Monitoring for Low-Risk DCIS (LORIS) trial is studying the safety of monitoring core-biopsy diagnosed low-risk ductal carcinoma in situ (DCIS) without excision. We sought to determine the incidence and characteristics of synchronous invasive carcinoma found in LORIS-eligible women who underwent excision, as this knowledge is essential in assessing the safety of observation alone. Methods. Women meeting LORIS eligibility criteria (age C46 years, screen-detected calcifications, non-high-grade DCIS diagnosed by core biopsy, absence of nipple discharge, or strong family history of breast cancer) who underwent surgical excision from 2009 to 2012 were identified. Histologic findings of excision specimens were reviewed. Results. Overall, 296 LORIS-eligible cases were identified; 58 (20 %) had invasive carcinoma on final pathology (90 % invasive ductal, 78 % [1 mm in size, 21 % high grade, 3 % triple negative, 9 % HER2 amplified). Of these, 18 (31 %) were pT1b or larger and 3 (5 %) were pN1. Among eligible upgraded cases, 90 % received radiation, 89 % received endocrine therapy, and 18 % were recommended chemotherapy. Women upgraded to invasive carcinoma were more likely to have intermediate-grade DCIS on core biopsy and to have undergone mastectomy. Conclusions. Among LORIS-eligible women, 20 % had invasive carcinoma at surgical excision that was heterogeneous in grade, size, and receptor status. Information gained from surgical excision influenced receipt of adjuvant radiation and endocrine therapy in most patients, and indicated benefit from chemotherapy in 18 % of patients. Surgical excision is warranted until additional risk stratification is available to identify a cohort of DCIS patients at lower risk for clinically significant synchronous invasive carcinoma.
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Ductal carcinoma in situ (DCIS) represents a heterogeneous pre-invasive breast lesion which harbors the potential for the progression to invasive carcinoma. 1 While the natural history of untreated DCIS is not well studied, two early studies reported a 40-50 % rate of progression to invasive disease by 10-15 years among women with unrecognized low-grade DCIS diagnosed as benign disease in an excisional biopsy. 2, 3 Given that nearly half of patients with DCIS may not be at risk for disease progression, there is increasing concern regarding the potential overtreatment of this pre-invasive lesion 4 , resulting in significant interest in identifying patients at very low risk for disease progression who may safely omit surgery and radiation therapy. The Surgery Versus Active Monitoring for LowRisk DCIS (LORIS) 5 trial is studying the safety of observation alone for a select cohort of patients with non-highgrade DCIS diagnosed by core needle biopsy. The primary outcome of the trial is the difference in invasive breastcancer-free survival at 5 years among women treated with observation alone compared with standard surgical excision.
Identifying patients with DCIS who harbor undiagnosed synchronous invasive carcinoma is essential in assessing the safety of observation alone. A meta-analysis reported an overall 21 % rate of upgrade to invasive cancer at the time of surgical excision among patients with non-highgrade DCIS diagnosed on needle biopsy 6 , but the rate of upgrade for women meeting all LORIS study eligibility criteria is currently unknown. We sought to determine the upgrade rate to invasive carcinoma for women with nonhigh-grade DCIS diagnosed by core needle biopsy who meet all clinical and pathologic LORIS trial eligibility criteria.
METHODS
Following Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Review Board approval, all women with core needle biopsy-proven non-high-grade DCIS alone who underwent breast surgery at our institution between 2009 and 2012 were identified. During this time period, vacuum-assisted core needle biopsy was routinely used. Figure 1 summarizes the inclusion and exclusion criteria for the LORIS trial; these characteristics were used to select the current study patient population. Women aged C46 years with screen-detected calcifications and nonhigh-grade DCIS diagnosed by vacuum-assisted core needle biopsy were selected. Among this cohort of patients with screen-detected mammographic calcifications, some underwent additional breast imaging with ultrasound (US) or magnetic resonance imaging (MRI), including 106 who underwent breast US and 104 who underwent MRI. Women were excluded due to the presence of a mass component on any breast imaging modality, nipple discharge, strong family history of breast cancer, or a personal history of invasive breast cancer or ipsilateral DCIS. For this study, strong family history was defined as two or more first-and/or second-degree relatives with a history of breast cancer.
Clinicopathologic Ò ; Genomic Health, Redwood City, CA, USA). Clinicopathologic features were compared between women with and without an upgrade to invasive carcinoma at surgical excision. Characteristics of the invasive carcinomas found at surgical excision were described. Continuous variables were summarized using median and range, and compared using the Wilcoxon test.
• Age ≥ 46 years Categorical variables were summarized using frequency and percentage, and compared using Fisher's exact test. All statistical analysis was carried out in R 3.1.1 (R Foundation, Vienna, Austria), and p values \0.05 were considered significant.
RESULTS
Overall, 296 cases were identified with non-high-grade DCIS diagnosed by core needle biopsy and meeting all LORIS trial eligibility criteria during this 4-year time period. Table 1 summarizes the clinicopathologic characteristics of the entire cohort. Median patient age was 57 years (range 46-84 years). No patient had a known BRCA mutation, and 44 % had one first-or second-degree family member with a history of breast cancer. Among the 296 cases, information regarding the type of core needle biopsy performed at the time of DCIS diagnosis was available for 254 (86 %) cases, all of whom underwent a vacuumassisted core needle biopsy. The gauge of the biopsy needle was 8 or 9 in 141 (62 %) patients, 10 or 11 in 81 (36 %) patients, 12 or 14 in 5 (2 %) patients, and unknown in 69 patients. The majority of patients had mixed architecture (83 %) and intermediate-grade (82 %) DCIS.
Among 296 cases meeting all LORIS trial eligibility criteria, 58 (20 %) were upgraded to invasive cancer at the time of surgical excision. 1 Clinicopathologic features of the entire study population (n = 296) and among women with (n = 58) and without (n = 238) an upgrade to invasive carcinoma at surgical excision
Variable
Entire population (n = 296) Table 2 lists the characteristics of the 58 patients found to have invasive carcinoma at surgical excision. Among these upgraded patients, the overall median invasive tumor size was 0.3 cm (range 0.1-4 cm). A subset of patients had high-risk invasive carcinoma features, including 3 (5 %) with lymphovascular invasion, 2 (3 %) triple-negative tumors, 5 (9 %) HER2 overexpressing tumors, and 3 (5 %) patients with pN1 disease. In addition, 7 of the 50 hormone receptor-positive, HER2 negative tumors had high nuclear grade. Treatment recommendations for 57 of the 58 women upgraded to invasive carcinoma were available and included radiation therapy for 27 of 30 (90 %) patients who underwent BCS, and endocrine therapy for 47 of 53 (89 %) women with estrogen receptor (ER) positive tumors (Table 3) . Among 19 women with node-negative, ER positive invasive cancer C5 mm in size, 13 had data available from the 21-gene recurrence score (OncotypeDX Ò ); 4 women had intermediate-or high-risk recurrence scores, while 9 had low-risk scores. In total, 45 % (26/58) of cases had tumor pathology that warranted genomic profiling or consideration for chemotherapy. Ten of 57 (18 %) patients with treatment information available were recommended to undergo chemotherapy for either high or intermediate genomic profile scores, node-positive disease, HER2 amplified or triple-negative tumors, or a combination of high-risk tumor features.
DISCUSSION
In our experience, LORIS eligibility criteria did not identify a population of women with DCIS at low risk for upgrade to invasive carcinoma at surgical excision, with an overall upgrade rate of 20 %, even among this highly selected patient population. While one study by Soumian et al. reported zero upgrades to invasive cancer among a small cohort of 19 patients with low-grade DCIS on core biopsy who met the LORIS criteria 7 , our reported upgrade rate is nearly identical to that found by Brennan et al. 6 in a meta-analysis reporting on 1736 patients diagnosed with DCIS by core needle biopsy. The overall reported upgrade was 26 % (range 23-30 %) among all patients, with a 21 % (range 15-28 %) upgrade to invasive carcinoma seen specifically among patients selected only for the presence of non-high-grade DCIS on core needle biopsy.
While others have reported an increased risk of upgrade to invasive carcinoma with the presence of clinical highrisk features such as a mass on imaging 8 or younger age 9 , our analysis excluded such patients. Our population of In contrast, among the 53 patients with low-grade DCIS alone on core biopsy, only four women (7 %) were upgraded to invasive carcinoma on final pathology. The finding that patients undergoing mastectomy were more prone to harboring a synchronous invasive carcinoma is likely related to the extent of disease at initial presentation. Extent of calcifications has previously been shown to be associated with the risk for upgrade to invasive carcinoma among women with core biopsy-proven DCIS. [9] [10] [11] [12] The LORIS trial is enrolling women with both low-and intermediategrade DCIS on core needle biopsy, and does not include a size limitation for mammographic calcifications. Our results suggest that, within this population, there remains a spectrum of risk for the presence of synchronous invasive carcinoma. Interestingly, the LORD (Low Risk DCIS) 13 study is a second European trial with a similar objective to the LORIS trial, but with slightly different eligibility criteria. The LORD study is limited to women with screendetected low-grade DCIS on core biopsy, excluding those with intermediate-grade lesions. Furthermore, additional eligibility criteria are included to better assess larger areas of calcifications, including additional mandatory core biopsies for patients with microcalcifications spanning [4 cm, or multicentric disease. Based on our findings, these additional inclusion criteria may result in a select population of patients with DCIS at lower risk for synchronous invasive carcinoma.
An important consequence of the identification of invasive carcinoma at the time of surgical excision is the potential change in adjuvant therapy recommendations. Unlike the situation in invasive carcinoma, radiation therapy after BCS for DCIS does not improve survival, 14 and the acceptance of endocrine therapy is substantially lower among women with DCIS than in those with invasive cancer. Furthermore, chemotherapy and targeted anti-HER2 therapy are not utilized for the management of DCIS. We have previously reported adjuvant therapy use among larger cohorts of patients with DCIS treated at our institution, with utilization of radiation therapy in recent years for women with DCIS following BCS at approximately 60 %, and the use of endocrine therapy substantially lower, at approximately 23 %, with no patients receiving chemotherapy. [15] [16] [17] Similar utilization of adjuvant therapy for patients with DCIS has been reported from national database reviews. According to National Cancer Institute Surveillance Epidemiology and End Results (SEER) data, approximately 35-40 % of women managed with BCS for DCIS in 2005 did not receive adjuvant radiation therapy. 18 In addition, in a review of over 206,000 women with DCIS reported to the National Cancer Database between 2005 and 2012, the minority of women (37 %) received adjuvant endocrine therapy. 19 Among the 59 cases with an upgrade to invasive carcinoma in the current study, nearly 90 % of eligible patients received adjuvant endocrine therapy and radiation 20 This assumption supports the notion that if non-high-grade DCIS is managed with observation alone, any invasive component will be lowgrade, detected on subsequent imaging at an early stage, and unlikely to require chemotherapy. Interestingly, the invasive cancers identified among this population of women with non-high-grade DCIS on core needle biopsy meeting all LORIS eligibility criteria were heterogeneous in regard to tumor grade, size, and receptor status. Six percent of the entire study population had poor prognostic invasive tumor features, including triple-negative, HER2 overexpressing, high-grade, T2, presence of lymphovascular invasion, or node-positive disease identified at the time of surgical excision. In addition to the standard recommendations for radiation therapy or endocrine therapy in the setting of invasive carcinoma, 45 % of the upgraded cases had tumor pathology that warranted genomic profiling or consideration for chemotherapy, and, ultimately, 18 % (n = 10) of patients with invasive carcinoma were recommended to receive adjuvant chemotherapy. Of the 10 patients recommended to receive chemotherapy, follow-up is missing for one patient, and one patient refused any additional therapy. The remaining eight patients received chemotherapy. While patients with features warranting chemotherapy likely benefited from the finding of invasive carcinoma, the remainder of patients with an upgrade likely benefited from the findings on final pathology as well, as over 90 % of these patients received additional adjuvant therapy with radiation and/or endocrine therapy, treatments known to improve survival among women with invasive breast cancer. Interestingly, the four tumors identified in patients with low-grade DCIS on core biopsy in this study were all subcentimeter, hormone receptor-positive, and HER2 negative cancers, while the patients with intermediate-grade DCIS on core biopsy were found to have a mix of tumor features on final pathology.
As noted, considerable interest exists regarding the study of lesser treatment for low-risk DCIS, including the omission of surgical excision. 5, 13, 21 While the goal of managing a non-invasive breast lesion must be balanced with the risk of the proposed therapy, the risk of surgical excision is low, with rates of short-term complications reported at \2 % among 6600 women reported to the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database who underwent BCS and SLNB; 22 therefore, the associated surgical morbidity is likely even lower following excision alone. While postoperative complications are rare, there is potential for long-term morbidity following breast surgery, including chronic post-surgical pain and dissatisfaction with cosmesis. 23, 24 However, given the overall 20 % rate of upgrade to invasive carcinoma, and the heterogeneity of the identified tumors, surgical excision should remain as the initial management of non-high-grade DCIS diagnosed by core biopsy until additional risk stratification is available to identify a population at lower risk for clinically significant synchronous invasive carcinoma. Our data suggest that the LORIS criteria do not adequately define such a low-risk DCIS population.
Our study is limited by its retrospective nature and lack of central radiology and pathology re-review. However, all pathology slides were interpreted, or, in the case of biopsies, performed elsewhere, and re-reviewed by highvolume dedicated breast pathologists. The same practice was employed for imaging review.
CONCLUSIONS
Women with screen-detected, non-high-grade DCIS diagnosed by core biopsy who met all LORIS trial eligibility criteria have a 20 % risk of upgrade to invasive carcinoma at the time of surgery excision. For nearly all of these, standard systemic and radiation therapy was influenced by the findings at excision. Outside of a clinical trial, given the clinically relevant rate of upgrade and the heterogeneity of the invasive carcinomas identified, surgical excision is warranted until additional risk stratification is available that identifies a population at lower risk for clinically significant synchronous invasive carcinoma.
